logo-loader
TSX:CRDL OTCQX:CRTPF

Cardiol Therapeutics

Receive alerts
Market:
TSX
Market Cap:
$76.72 m
Price
2.34 CAD
Change
-1.27%
52 weeks high
5.40
52 weeks low
1.87

In brief

Cardiol Therapeutics (TSX: CRDL; OTCQX: CRTPF) produces pharmaceutical cannabidiol and develops innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. Their lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, THC free (<5 ppm), and formulated to be one of the safest and most consistent cannabidiol formulations. An international clinical study of CardiolRx is planned in acute myocarditis, a condition caused by inflammation in heart tissue and the most common cause of sudden cardiac death in young people. Cardiol is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol directly to sites of inflammation in the heart associated with heart failure.